We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Seasun Biomaterials Secures FDA Emergency Use Authorization for Second COVID-19 Rapid Detection Kit

By LabMedica International staff writers
Posted on 25 May 2020
Print article
Image: AQ-TOP™ COVID-19 Rapid Detection Kit (Photo courtesy of Seasun Biomaterials, Inc.)
Image: AQ-TOP™ COVID-19 Rapid Detection Kit (Photo courtesy of Seasun Biomaterials, Inc.)
Seasun Biomaterials, Inc. (Daejeon, Korea) has received Emergency Use Authorization (EUA) from the US Food and Drug Administration for its second COVID-19 assay AQ-TOP COVID-19 Rapid Detection Kit following the completion of FDA EUA (April-27) of its U-TOP COVID-19 Real-Time Detection Kit.

The AQ-TOP technology enhances analytical speed, sensitivity and specificity of the conventional molecular methods by combining isothermal amplification and PNA (Peptide Nucleic Acid) detection probe, which has high accurate binding efficiency to the target nucleic acid. This kit targets the ORF1ab gene of the SARS-CoV-2 with an endogenous control human RNase P gene. Customers need not purchase any additional equipment and can use their existing real-time PCR instrument which is frequently used for COVID-19 diagnosis. The average number of specimens that can be tested per unit (12 hours per day) is 3,400, which is 5-6 times faster than before. The company now plans to provide the kit globally and hopes that its advantage of rapid COVID-19 diagnosis will contribute to quick follow up.

Related Links:
Seasun Biomaterials, Inc.


Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.